Norwell Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 28-12-2024
- Paid Up Capital ₹ 0.50 M
as on 28-12-2024
- Company Age 8 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.50 M
as on 28-12-2024
- Satisfied Charges ₹ 2.53 M
as on 28-12-2024
- Revenue -1.51%
(FY 2023)
- Profit 89.87%
(FY 2023)
- Ebitda 617.56%
(FY 2023)
- Net Worth -3.67%
(FY 2023)
- Total Assets 24.21%
(FY 2023)
About Norwell Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹4.50 M. The company has closed loans amounting to ₹2.53 M, as per Ministry of Corporate Affairs (MCA) records.
Rachana Jain and Akash Jain serve as directors at the Company.
- CIN/LLPIN
U51909TG2016PTC112435
- Company No.
112435
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Oct 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Norwell Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rachana Jain  | Director | 14-Oct-2016 | Current |
| Akash Jain | Director | 14-Oct-2016 | Current |
Financial Performance of Norwell Pharma.
Norwell Pharma Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 1.51% decrease. The company also saw a substantial improvement in profitability, with a 89.87% increase in profit. The company's net worth dipped by a decrease of 3.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Norwell Pharma?
Unlock access to Norwell Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹4.50 M
₹2.53 M
Charges Breakdown by Lending Institutions
- Yes Bank Limited : 0.45 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 Dec 2020 | Yes Bank Limited | ₹4.50 M | Open |
| 29 Dec 2018 | Others | ₹2.53 M | Satisfied |
How Many Employees Work at Norwell Pharma?
Unlock and access historical data on people associated with Norwell Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Norwell Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Norwell Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
